Orgenesis

Company Overview

Snapshot

Founded in January 2008, Orgenesis operates with 11–50 employees and has raised a total of $18.2 million across five funding rounds. The company went public on NASDAQ in March 2018, marking a significant milestone in its growth trajectory.

Business overview

Orgenesis is a global biotech company specializing in cell and gene therapy, utilizing a unique Biotech Platform to develop life-changing treatments. The company focuses on providing these therapies at the Point of Care (POCare) to a large patient population, aiming to reduce costs. Its platform integrates a pipeline of POCare Therapeutics, customized POCare Technologies for closed processing, and a global POCare Network of partners. Orgenesis operates within the Health Tech & Life Sciences sector, with a focus on pharmaceuticals, biotechnology, and healthcare providers.

Strategic signal

In March 2025, Orgenesis announced the acquisition of certain Neurocords LLC assets, strengthening its regenerative medicine portfolio with spinal cord injury therapies. This strategic move signals the company's commitment to expanding its therapeutic offerings and enhancing its capabilities in a critical area of regenerative medicine, indicating a proactive approach to market expansion and product diversification for investors.

Company Intelligence Q&A

When did Orgenesis go public?

Orgenesis went public on NASDAQ in March 2018.

What was a key strategic acquisition for Orgenesis in 2025?

In March 2025, Orgenesis acquired certain Neurocords LLC assets, which strengthened its regenerative medicine portfolio with spinal cord injury therapies.

What was a significant partnership announced by Orgenesis in 2023?

In March 2023, Orgenesis signed a Memorandum of Understanding (MOU) with the University of California, Davis, to develop a collaboration agreement for deploying Cell and Gene Therapy Mobile Processing Units and Labs across California.

What was a notable investment received by Orgenesis in 2023?

In May 2023, Orgenesis secured an additional $5 million investment from Metalmark Capital to accelerate the growth of its Point-of-Care service subsidiary.

What was a key operational development for Orgenesis in late 2023?

In November 2023, Orgenesis was ranked as the 171st fastest-growing company in North America on the 2023 Deloitte Technology Fast 500™.